Reuters logo
BRIEF-Bristol-Myers says Checkmate -078 trial stopped early for demonstrating superior overall survival
December 1, 2017 / 12:44 AM / 14 days ago

BRIEF-Bristol-Myers says Checkmate -078 trial stopped early for demonstrating superior overall survival

Nov 30 (Reuters) - Bristol-Myers Squibb Co:

* CHECKMATE -078, A PIVOTAL, MULTINATIONAL PHASE 3 OPDIVO (NIVOLUMAB) LUNG CANCER TRIAL WITH PREDOMINANTLY CHINESE PATIENTS, STOPPED EARLY FOR DEMONSTRATING SUPERIOR OVERALL SURVIVAL

* ‍CHINA FOOD AND DRUG ADMINISTRATION ACCEPTED MARKETING APPLICATION FOR OPDIVO​

* ‍SAFETY PROFILE OF OPDIVO WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES IN SOLID TUMORS​

* BRISTOL-MYERS- OPDIVO SHOWS SUPERIOR OVERALL SURVIVAL COMPARED TO DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below